especially for those patients considered low-risk (DSA À ), but who are presensitized against their donor.
This would improve patient risk stratification and post-Tx monitoring for implementation of personalized induction and immunosuppression maintenance. DSAs are isotype-switched IgG antibodies (Abs) directed against HLA molecules that depend on T-cell help for their generation. T follicular helper (T FH ) cells, a subset of memory (CD45RO þ ) CXCR5 þ CD4 þ T cells, participate in the germinal center formation in secondary lymphoid organs, where they provide critical cognate antigenic help to B lymphocytes inducing their differentiation into memory B cells, short-lived plasmablasts, and/or long-lived plasma cells that secrete high-affinity, isotype-switched IgG responses. [8] [9] [10] Human peripheral blood CXCR5 þ CD4 þ T cells, also called circulating (c)T FH cells, are considered the counterparts of germinal center-T FH cells and represent approximately 20% of peripheral blood memory CD4 þ T cells.
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C T FH cells are functionally heterogeneous and, based on their distinct chemokine receptor coexpression and ability to produce cytokines, comprise Th1-cT FH (CXCR3 þ ), Th2-and Th17-cT FH (CXCR3 À ) subsets. These subsets convey critically different somatic hypermutation instructions to antigen (Ag)-specific B cells that distinctly shape antibody responses. 12, 14 In addition, differential coexpression of PD-1 and CD62L further identifies cT FH . 11 Monitoring cT FH cell subset distribution and phenotypes in human blood has been shown to be a good surrogate to identify T FH cell activation (i.e., Ab responses) in healthy humans after vaccination or in patients with chronic Ab-mediated diseases. 13, 15, 16 Approximately 60% of solid organ transplant recipients in the United States receive thymoglobulin, a Tcell depleting agent, as induction therapy, whereas approximately 20% receive the non-T-cell depleting anti-IL-2Ra blocker basiliximab. Thymoglobulin induction was shown to trigger significant and protracted depletion of total CD4 þ T lymphocytes. [17] [18] [19] Lymphopenia-induced proliferation (LIP) after depletion initiates repopulation of CD4 þ T cells with a phenotype skewed toward effector memory pool and a significant decrease in the naïve pool. 20 Conversely, literature reports that the frequency and memory differentiation of CD4 þ T cells post-basiliximab induction remains unchanged. 19 However, the effect of induction therapy on cT FH cell levels and phenotype postKTx, and how these impact changes in cT FH cells during DSA responses have not been thoroughly investigated in the field of organ transplantation. [21] [22] [23] [24] Our goal here was to elucidate in a longitudinal and cross-sectional manner the impact of this T-cell depleting agent thymoglobulin on the levels and phenotype of cT FH cells and correlate those with the development of DSA post-KTx. Basiliximab induction was used as a control group.
METHODS

Patients and Immunosuppression
A cohort of consecutive 56 first-time living donor ABO-compatible KTx recipients (thymoglobulin-induced n ¼ 34 and basiliximab-induced n ¼ 22) was recruited between October 2011 and September 2014 following informed consent at Christ Hospital and University of Cincinnati (TCH no. 11-44; IRB no. 11-06-09-05EE) and enrolled into a prospective 12-month study (Figure 1) . By the end of study follow-up, 31 thymoglobulin-and 20 basiliximab-induced patients remained eligible for our immunologic analyses. There were no significant differences in gender, number of HLA mismatches, degree of presensitization (by percent reactive Ag, flow cytometry cross-match, DSA, history of pregnancies and transfusions) and maintenance immunosuppression between cohorts ( Table 1) . Etiologies of end-stage renal disease (ESRD), including autoimmune and inflammatory kidney disease are found in Supplementary Table S1 . In addition, 13 gender-and age-matched healthy control (HC) volunteers were recruited on informed consent at the University of Pittsburgh (IRB no. 0608014) and used as controls (Table 1 ).
An independent cross-sectional cohort of thymoglobulin-induced patients (n ¼ 23) was recruited from the University of Pittsburgh Medical Center (UPMC) (IRB no. 12030552) and included in the study as part of a validation group (Figure 1, Supplementary  Tables S2 and S3 ).
Whole-Blood Collection
Blood samples were obtained prospectively from pre-Tx to 30, 90, 180, 270 , and 360 days post-KTx from the Cincinnati cohort ( Figure 1c ) and cross-sectional from the UPMC cohort (Figure 1d ). One milliliter of whole blood was used for flow cytometry, whereas the remainder to isolate plasma and peripheral blood mononuclear cells (PBMCs) by Ficoll-Hypaque (GE Healthcare, Uppsala, Sweden) and subsequently banked. Overall, a total of 307 samples were collected and analyzed by flow cytometry for cT FH characterization and by single-bead Luminex for anti-HLA antibody detection.
DSA Definition
We classified patients as stable (no DSA, no rejection or infection throughout follow-up) or DSA þ . DSA þ patients were defined as patients who became positive for DSA post-KTx ($1000-mean fluorescence intensity [MFI] ). According to this definition, 19 patients (Cincinnati cohort n ¼ 12 and UPMC cohort n ¼ 7) were classified as DSA þ (Table 2 and Supplementary Table S3 ). Those patients who developed DSA within 6 weeks post-KTx are considered newly detected memory DSA over true de novo DSA.
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Detection of DSA Nonheparinized blood was collected to isolate serum for the measurement of anti-HLA-A, -B, -C, -DRB1, DR51/52/ 53, and -DQB antibodies at all blood sampling time points using the Luminex single-Ag bead assay (One Lambda, Inc., Canoga Park, CA) as previously described. 27 Results were considered to be positive if DSA MFI $ 1000; pattern at MFI 400-999; and negative if MFI < 399. All positive DSA samples were subsequently tested for C1q to exclude any prozone effect.
Phenotypic Analyses of T-Cell Subsets by Flow Cytometry
Whole-blood aliquots were incubated with a mixture of monclonal Abs: anti-CD3, -CXCR5, -CD4, -CXCR3, -CD25 (BD, San Jose, CA) and -CD45RO, -PD1, -CD62L, CD127 (eBioscience, San Diego, CA), in the dark for 30 minutes at room temperature. Samples were then incubated with red blood cells lysis buffer (BD) for 10 minutes at room temperature, washed twice, and fixed with fixation/permeabilization buffer (eBioscience) for 40 minutes at 4 C. For T regulatory cells (T REG ) and Ki67 detection, cells were further permeabilized with permeabilization buffer (eBioscience) and incubated in the dark for 30 minutes at 4 C with anti-FOXP3 and (maximum 500 mg), followed by taper discontinued by POD 8. Patients in the T-cell-nondepleted group received mycophenolic acid (MPA) preload 2 weeks before kidney transplantation (KTx) (720 mg p.o. 2x daily) followed by basiliximab induction at 20 mg i.v. Â 2 doses given on POD 0 and 4 plus a steroid taper as described previously. Maintenance immunosuppression consisted of Tacrolimus (TAC) 0.05 mg/kg orally twice daily (target trough level at POD 0-89 ¼ 8-15 ng/ml and POD > 90 ¼ 5-10 ng/ml) and MPA 720 mg orally twice daily starting on the day of transplantation for both cohorts. Blood samples were prospectively collected up to 1 year post-KTx as indicated. The pre-Tx sample was always collected before induction and/or MPA preload. (d) Diagram of induction therapy/immunosuppression regimen from the validation UPMC cohort. Patients received thymoglobulin at 1.5 mg/kg per dose i.v. Â 5 doses given on POD 0-5 plus premedication with acetaminophen 650 mg, diphenhydramine 25 mg, and daily methylprednisolone dose-tapering 1 hour 30 minutes before infusion for 5 days. Maintenance immunosuppression consisted of TAC 0.05-0.1 mg/kg orally twice daily (target trough level at POD 0-90 ¼ 6-12 ng/ml, POD 91-365 ¼ 5-8 ng/ml, and POD >366 ¼ 3-7 ng/ml) and MPA 720 mg orally twice daily starting on the day of transplantation. anti-Ki67 (eBioscience), washed twice, and immediately acquired. All events were acquired using a Fortessa (BD) cytometer and analyzed with FlowJo software (Tree Star, Ashland, OR). In addition, we applied tdistributed Stochastic Neighbor Embedding algorithm (FlowJo) and integrated the fluorescence intensity of phenotypic markers into a consensus map to visualize the overall differences of cT FH cell subset composition measured by cell cluster density.
Cytokine Determination in Plasma
Cytokine measurements were performed using Luminex bead-based assays at the University of Pittsburgh Luminex Core Laboratory (P30CA047904). Kits including interleukin (IL)-12p70, IL-27, IL-10, IFN-g, IL-6, IL-17a, IL-21, and IL-23 were purchased from Millipore (EMD Millipore, Billerica, MA).
Cytokine Determination by Intracellular Staining and Flow Cytometry
Banked frozen responder PBMCs were thawed and rested overnight. Responder PBMCs were stimulated with donor cell lysate at 1:5 ratio for 6 hours in the presence of Golgi-plug (BD) and Monensin (eBioscience) at 37 C, 5% CO 2 . Cells were then washed, and surface stained with anti-CD3 (Biolegend, San Diego, CA), -CD8, -CXCR5, (BD) for 20 minutes at 4 o C, washed, and fixed with 1% paraformaldehyde (Sigma, St. Louis, 
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MO) for 40 minutes. Subsequently, the cells were permeabilized and incubated with mouse serum (Invitrogen, Frederick, MD) for 5 minutes at room temperature, followed by anti-CD40L (eBioscience) and IL-21 monclonal Abs (BD) for 30 minutes at room temperature. Cell were washed and immediately acquired as described previously.
Statistical Analysis
Differences across demographic variables were tested with Fisher exact (for categorical variables), whereas for continuous variables, Student t test and 1-way analysis of variance were used. To evaluate differences for cross-sectional data, mean AE SEM were calculated and compared across groups (HC vs. thymoglobulin; HC vs. basiliximab; thymoglobulin vs. basiliximab) using the 2-tailed Student t test or MannWhitney test according to data distribution. To evaluate group differences between thymoglobulin and basiliximab over time (longitudinal data), and the effect of time within each group, we used a linear mixed model with a random intercept to account for withinsubject correlation over time and indicator variables for the treatment at each time point. Mean AE SEM was calculated at each time point and differences from baseline (for each time point within each treatment group) were assessed using linear regression. All results were considered statistically significant if the P value was #0.05. 
RESULTS
cT FH cells, and of overall data are shown in Figure 2a d. Results demonstrate that patients with ESRD display similar levels of CD45RO The cT FH cell memory phenotype was significantly skewed from CM toward EM in the thymoglobulin group compared with basiliximab-induced patients who maintained their memory profiles similar to those of HC (Figure 3c ). In addition, cT FH cells from thymoglobulin-induced patients displayed significant upregulation of PD-1 expression from low to intermediate at all time points or high at 90 and 180 days postdepletion compared with their own pre-KTx levels, with those of the basiliximab group and HC (Figure 3d ). This elevation in PD-1 expression, accompanied by the decrease in CM suggests that due to LIP, cT FH cells become activated after thymoglobulin induction.
Moreover, while the absolute counts of Th1-cT FH and Th2þTh17-cT FH cells were significantly depleted by thymoglobulin induction, the proportion (%) of these subsets was altered in the circulation of these patients with significant elevation of Th1-cT FH cells ( Figure 3e) Figure S2A) . Conversely, LIP of overall CD4 þ T-cell pool did not differ between DSA þ and stable patients (Supplementary Figure S2A) .
No elevated Ki67 þ was detected in basiliximabinduced patients (Supplementary Figure S2A) . In addition, the % EM cT FH cells from DSA þ patients was significantly higher than those of stable patients (180 and 270 days) in the thymoglobulin group (Supplementary Figure S2B) .
Together, these data demonstrate that depleting versus nondepleting induction therapies have different impacts on cT FH cell phenotype post-KTx.
Cross-Sectional Unsupervised t-Distributed Stochastic Neighbor Embedding-Clustering Highlights the Distinct Effect of Induction Therapy on cT FH Cell Phenotype We next analyzed cross-sectionally the levels and the phenotype of cT FH cell subsets in the first blood sample obtained after DSA occurrence post-KTx (ranging (Figures 4 and 5) . Peripheral blood of stable patients in both cohorts and HC was used as controls.
TRANSLATIONAL RESEARCH
The consensus t-distributed Stochastic Neighbor Embedding (tSNE) map generated by concatenating 14 individual maps was overlaid with CXCR3, PD-1, and CD62L markers to further allow, in an unsupervised phenotypic analysis of cT FH cell compartments, the identification of cell clusters with unique phenotypic patterns (Figure 4a ). Subsequently, we de-concatenated the consensus map into 5 group component maps that showed landscapes with unique cell cluster intensities and patterns depending on the group, and with some missing cell clusters in HC and variable cell cluster densities and localization among KTx groups (Figure 4b) . Moreover, gating on the highest cell density cluster in each group map, we further compared the CXCR3, PD-1, and CD62L expression from the consensus map (Figure 4a ). This concomitant analysis allowed us to conclude that Pre-Tx 30d 90d 180d 270d 360d
Pre-Tx 30d 90d 180d 270d 360d
Pre-Tx 30d 90d 180d 270d 360d Figure S4) .
DSA þ KTx Patients, Regardless of Induction Therapies, Show Increased cT FH /T REG Ratios
It is recognized that effector T-cell responses are tightly modulated by T REG , and that any disturbances of this cell subset may lead to rejection. 28 We therefore assessed the levels of circulating T REG (
at the same time points used to monitor cT FH cells. We found that the % T REG was overall decreased in the thymoglobulin group compared with patients in the basiliximab group or to HC (Figure 6a ). FH and overall data (HC, n ¼ 9; thymoglobulin, stable n ¼ 9 and DSA þ n ¼ 6; basiliximab, stable n ¼ 4 and DSA þ n ¼ 2). (c) Gating strategy to identify the frequency of Th1-cT FH cells (left) and of EM distribution (right) and the overall data (HC, n ¼ 11; thymoglobulin, stable n ¼ 15 and DSA þ n ¼ 9; basiliximab, stable n ¼ 7 and DSA þ n ¼ 3). (d) Gating strategy to identify the frequency of Th2þTh17-cT FH cells (left) and of EM distribution (right) and the overall data (HC, n ¼ 11; thymoglobulin, stable n ¼ 15 and DSA þ n ¼ 9; basiliximab, stable n ¼ 7 and DSA þ n ¼ 3). Each dot represents 1 subject, and the horizontal lines are of the mean values. HCs are represented by filled circles, thymoglobulininduced patients by filled squares, and basiliximab-induced patients by open squares. Two-tailed Student t test or Mann-Whitney test was used according to data distribution. *P < 0.05; **P < 0.01; ***P < 0.001. (Figure 7a ). These proinflammatory cytokines are known to promote human T FH cell generation 29 and to shape their fate, suggesting that these programs may be easily activated post-KTx.
IL-17a, IL-21, and IL-23 compared with stable patients
To further test whether memory IL-21 þ cT FH cells reactive to donor allo-Ag are detectable in the circulation of patients with ESRD pre-Tx, we set-up shortterm (6-hour) stimulation assays consisting of patients' PBMCs pulsed or not with their donor cell lysate. Our results indicate that patients with ESRD who developed DSA post-KTx carried significantly more circulating memory (CD40L þ IL-21 þ ) cT FH cells before KTx than patients with ESRD who remained stable post-KTx (Figure 7b) . All these results demonstrate that patterns of proinflammatory cytokine milieu favorable for cT FH cell development, as well as concomitant presence of memory allo-reactive IL-21 þ cT FH cells can be detected in ESRD pre-KTx and may suggest increased risk for DSA generation post-KTx. These results also underscore the importance of pre-KTx screening for cellular donor-reactive memory cT FH cells in patients with ESRD.
DISCUSSION
The goal of the current study was to explore the cT FH cell phenotypic changes triggered by induction therapy at KTx and by DSA occurrence. Our results demonstrate that thymoglobulin induction and subsequent LIP triggers significant cT FH cell depletion and homeostatic proliferation accompanied by preferential expansion of Th1-cT FH with EM and PD-1 upregulation. Furthermore, in thymoglobulin-induced patients, the activated Th1-cT FH repopulation post-KTx and the increased Th1-cT FH :T REG ratio correlate with DSA occurrence. Conversely, in the basiliximab group, the Th2þTh17-cT FH :T REG ratio was changed at DSA occurrence. These underscore different mechanisms of cT FH /T REG homeostasis post-KTx triggered by different induction therapies and the presence or absence of LIP. Because our analyses revealed that LIP and subsequent repopulation of the thymoglobulin-resistant cT FH cells specifically lowered their threshold for activation and thus may render them susceptible targets to donor-Ag specific trigger, we postulate that long-term post-KTx, if under-immunosuppressed (during weaning) or if noncompliant, thymoglobulininduced patients may be vulnerable to DSA generation due to the persistence of activated cT FH cell phenotype.
Most randomized clinical studies so far have investigated the role of induction therapies on cellular rejection. These studies concluded that depleting therapy preferentially benefits sensitized KTx candidates by lowering T-cell-mediated rejection occurrence post-Tx compared with nondepleting induction therapies. 18, [30] [31] [32] [33] [34] However, the role of induction therapy on DSA occurrence is not well understood. 35 The very few published data on this topic resulted from singlecenter, nonrandomized clinical studies, with poor definition of de novo versus memory DSA status, and with variable clinical follow-up. In one study, the authors compared the T-cell depleting induction used in desensitized moderate risk patients with nondepleting induction used in low-risk patients. 36 Another singlecenter study reported DSA incidence in patients grouped together, regardless of their induction therapy. 37 Therefore, none of these studies are yet conclusive. Although our current study was not designed or powered to correlate the induction therapy with the incidence of DSA, it showed that thymoglobulin induction, unlike basiliximab, did significantly expand the proportion of activated cT FH cell with Th1 phenotypes. This suggests that LIP and subsequent early repopulation of the thymoglobulin-resistant cT FH cells specifically lowered their threshold for activation and thus rendered them susceptible targets to donorAg specific trigger if memory to donor (pre-Tx IL-21 þ cT FH testing) is present. We further postulate that long-term post-KTx, if under-immunosuppressed (i.e., during weaning or noncompliant), thymoglobulininduced patients may be also vulnerable to DSA generation due to the persistence of activated cT FH cell phenotype for at least 1 year post-Tx per our follow-up, and therefore should be closely monitored post-Tx. In a recent study, Hricik et al. 38 found that tacrolimus withdrawal in immune quiescent thymoglobulin-induced KTx recipients (with no history of DSA) had to be terminated prematurely because of unacceptable rates of de novo DSA occurrence in the tacrolimus withdrawal arm versus nonweaning. Although that was not a randomized prospective study to test DSA incidence after weaning in patients receiving or not induction therapy, our hypothesis is that those patients who developed DSA after weaning might have presented activated donor-specific cT FH precursors that were otherwise well controlled by tacrolimus. 17 In a recent publication, Chen et al. 23 showed that after thymoglobulin induction, maintenance immunosuppression only partially reduced CD40L and ICOS expression on CD3/CD28 activated cT FH ex vivo , and with no effect on IL-21 secretion, suggesting an inadequate block on T FH helper function by those drugs. Therefore, monitoring for the presence of activated donor-specific cT FH cells might be a critical step before weaning, but its importance still remains to be established in future studies.
Interestingly, de Graav et al. 39 found in a cohort of basiliximab-induced KTx patients that the absolute numbers of total cT FH (not only CD45RO þ cT FH ) postKTx were the highest in patients with preformed DSA (>5000 MFI cutoff), and when isolated, cT FH preserved their ability to provide IL-21-mediated Bcell help. Cano-Romero et al. 40 showed a role for different induction therapies on cT FH cells after KTx. Although their findings on the role of induction therapies on cT FH cells concur with our results reported here, the further focus of our studies diverged. We assessed the relationship of cT FH cells with DSA (donorAg specific responses) post-KTx, whereas they studied the relationship of cT FH cells with anti-HLA sensitization (not donor-Ag specific responses). 40 Therefore, future studies should consider standardization of cT FH cell gating strategy, distinction between HLA-Ab and DSA, and the threshold of DSA positivity.
The skewed representation of cT FH cell subsets that are differently modulated by induction therapy is important given the distinct ability of cT FH cell subsets to help B cells, and subsequently shape Ab responses. 41 The literature provides evidence that Th1-cT FH cells can primarily help memory B-cell differentiation into IgG-secreting plasmablasts, but are poor helpers for naïve B-cell differentiation, and thus are considered suboptimal helpers, unlike Th2-or Th17-cT FH cells who can help both naïve and memory B cells. 42 The effect of depleting versus nondepleting agents on T REG has been previously studied. 20, 43 In addition, published data suggest that T FH cell responses may be tightly modulated by T REG . 44 Our cross-sectional data indicate that differently polarized cT FH cells regardless of the induction therapy used may be regulated by T REG , suggesting that the T REG cells present in the circulation of patients decrease at DSA occurrence.
Our results underscore the potential importance of cellular monitoring for cT FH to enhance the detection of possible donor-Ag specific humoral sensitization preKTx. Currently available methods to detect humoral sensitization consist of measurements of circulating anti-HLA Abs in patients' serum. Methods for monitoring recipients' T cellular allo-reactivity using PBMCs with IFN-g enzyme-linked immunosorbent spot or intracellular staining and flow cytometry against a panel of allo-Ag or against donor-Ag have been previously developed and can identify patients at risk of cellular rejection post-KTx. [45] [46] [47] These assays do not address the issue of humoral sensitization and thus are not specific to detect the donor-Ag specific memory cT FH cell (and B-cell) pools. Therefore, "personalized" pre-Tx cellular screening for donor-Ag specific memory B cells 48, 49 We selected IL-21 for identifying humoral sensitization because it is the signature cytokine for functional T FH cells, critical for B-cell help and Ab responses, including allo-Ab/DSA responses. 52, 53 In addition to cellular screening, our results show that enzyme-linked immunosorbent assay monitoring of pre-KTx plasma may detect elevated T FH cell-friendly inflammatory cytokines in recipients who developed DSA post-KTx, as compared with those who remained stable. Inflammatory cytokines (IL-12p70, IL-21, IL-6, IL-17a) that shape T FH cell induction, polarization, and maintenance have been previously described. 29 These pre-Tx screenings in conjunction with measuring cT FH cell proliferation (Ki67 þ ) in thymoglobulin-induced patients in the first 3 months post-Tx may specifically identify patients at risk for DSA occurrence. Interestingly, this distinct kinetics of memory cT FH cell repopulation in DSA þ versus DSA À patients suggests a role for cT FH T-cell receptor stimulation by donor-Ag/ major histocompatibility complex class II in addition to cytokine stimulation. 54 All these potential clinically relevant tests need further validation on a larger number of patients to confirm their robustness and reliability in identifying correlations among induction therapy, memory cT FH , and DSA occurrence.
In conclusion, (i) thymoglobulin induction triggers protracted cT FH cell depletion, activation, and skewed polarization toward the Th1 phenotype compared with basiliximab induction; (ii) DSA þ KTx patients, regardless of induction therapies, show increased cT FH /T REG ratios; (iii) patients with ESRD who develop DSA post-KTx exhibit pre-Tx circulating donorspecific memory IL-21 þ cT FH cells and increased plasma levels of T FH cell-promoting inflammatory cytokines. Thus, future randomized controlled clinical trials to validate the present study should implement donor-Ag specific screening for detection of cellular presensitization (memory cT FH /B/T REG ), measurements of inflammatory cytokines for cT FH cell, and monitoring of Ki67 proliferation (for thymoglobulin induction) in addition to DSA measurements and characterization.
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